Clinical Trials Logo

Chronic Kidney Disease 5D clinical trials

View clinical trials related to Chronic Kidney Disease 5D.

Filter by:
  • Not yet recruiting  
  • Page 1

NCT ID: NCT06381076 Not yet recruiting - Clinical trials for Chronic Kidney Disease 5D

Examining the Impact of High-protein Oral Supplement With Liposomal Curcumin on Inflammation Markers and Oxidative Stress in Adults Undergoing Hemodialysis.

Start date: August 2024
Phase: N/A
Study type: Interventional

A 12-week double-blind randomized control trial will be conducted among adults on hemodialysis (n=15) to determine the impact of liposomal curcumin in a high-protein product on inflammation markers and oxidative stress. Participants will be randomized via a computer-generator into either the control or intervention group. Participants in each group will be given a total of 38 g of a high protein product with or without 7 mls of liposomal curcumin for a total of 8 weeks. At baseline, weeks 8 and 12, participants will have blood sampled and complete a 3-day 24-hour recalls (2 non-dialysis days and 1 dialysis day) and a quality of life survey.

NCT ID: NCT05234047 Not yet recruiting - Osteoporosis Clinical Trials

Study Evaluating Denosumab on Vascular and Bone Metabolism in Osteoporotic Chronic Kidney Disease (HDENOBS)

HDENOBS
Start date: May 2022
Phase:
Study type: Observational

Aim of this study is to evaluate in a population of osteoporotic chronic kidney disease patients the effect of denosumab: - on coronary artery calcification scores evolution after 24 months of followup - on abdominal aorta calcification scores evolution after 24 months of followup - on bone mineral density (femoral T-score) at 24 months - on bone mineral density evolution (femoral T-score) after 24 months of follow-up - on bone mineral density evolution (lumbar T-score) after 24 months of follow-up - on parameters of bone remodelling after 24 months of follow-up - on cardiovascular morbidity (cardiovascular events) and mortality after 24 months of follow-up - the tolerance after 24 months of follow-up